TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02152254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Therapy Based on Molecular Profiling
Description: Molecular profiling results are used to assign targeted therapy. Patients receive targeted therapy by participating in a Phase I or a Phase II clinical trial. If a clinical trial is not available, and a commercially available targeted therapy exists (Food and Drug Administration \[FDA\]-approved for another indication), patients can receive the FDA-approved drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-of-Care Therapy
Description: Standard-of-care treatment regimen will be left to the discretion of the treating physician.
Study: NCT02883634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific manipulation
Description: Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-specific manipulation
Description: Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
Study: NCT03746769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic Human Islet Cells
Description: islet cells transplanted into the portal vein in the liver

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrin 17
Description: Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
Study: NCT06112782

Intervention type: DEVICE
Group type: OTHER
Intervention: Keravive by Hydrafacial Treatments
Description: Scalp hydradermabrasion
Study: NCT03813979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach
Study: NCT02409992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training plus Emotion Coaching
Description: This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Training only
Description: This intervention will consist of a parent management training program called Helping the Noncompliant Child.
Study: NCT01372280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reminyl
Description: Galantamine Hydrobromide Tablets 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reminyl
Description: Galantamine Hydrobromide Tablets 4 mg
Study: NCT03905746

Intervention type: OTHER
Intervention: blood sample at Day 0
Description: 40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)

Intervention type: OTHER
Intervention: blood sample at Day 0
Description: 40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)

Intervention type: OTHER
Intervention: blood sample at Day 2 and Day 7
Description: 20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.

Intervention type: OTHER
Intervention: stool sample at Day 0
Description: stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.

Intervention type: OTHER
Intervention: stool sample at Day 0
Description: stool sample (2mL) will be performed at D0 (inclusion), at the time of routine exams.
Study: NCT01928524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS2w Dose level 1A
Description: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (60 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS2w Dose level 2A
Description: Docetaxel (30 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS2w Dose level 3A
Description: Docetaxel (40 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS2w Dose level 4A
Description: Docetaxel (50 mg/m2), Oxaliplatin (70 mg/m2) and S1 (70 mg/2) will be given every 2 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS3w Dose level 1B
Description: Docetaxel (40 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS3w Dose level 2B
Description: Docetaxel (50 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOS3w Dose level 3B
Description: Docetaxel (60 mg/m2), Oxaliplatin (100 mg/m2) and S1 (50 mg/2) will be given every 3 weeks. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered.
Study: NCT03285620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-034
Description: Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-034
Description: Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
Study: NCT00170716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortical Stimulation and rehabilitation
Description: Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
Study: NCT01252940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TDF
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TDF
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI
Description: Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: Ritonavir (RTV) was administered according to prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
Study: NCT02549183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific PRECISION Spinal Cord Stimulator System
Description: Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific PRECISION Spinal Cord Stimulator System
Description: Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific PRECISION Spinal Cord Stimulator System
Description: Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific PRECISION Spinal Cord Stimulator System
Description: Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
Study: NCT04487639

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics
Description: a nasopharyngeal swab for SARS-CoV-2 research by RT- qPCR will be performed on the day of semen collection. On the same day, serological tests will be carried out, and 30 to 50 days after, according to HAS specifications with methods validated by the National Reference Center
Study: NCT04277156

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L rhamnosus ATCC 53103
Description: 5 drops contain Lactobacillus rhamnosus 5x10\^9 CFU.
Study: NCT02377193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simulect
Description: Simulect IV 40 mg/day D0 and D4~and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
Study: NCT00592592

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: Once per day, 5 days a week for a total of 4 to 6 weeks.
Study: NCT02932033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tack fixation of mesh
Description: hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Synthetic glue fixation
Description: hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
Study: NCT04386421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video on oral hygeine instructions
Description: A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plaque disclosing tablets
Description: Plaque disclosing tablets:~Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %
Study: NCT00634166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamylon® For 5 % Topical Solution
Description: Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.

Intervention type: DRUG
Group type: OTHER
Intervention: Topical Antimicrobial/Antifungal Medications
Description: 'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
Study: NCT02581449

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3
Description: dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: empty soft gelatin capsules
Description: empty softgels of matched size, shape and color
Study: NCT00955591

Intervention type: OTHER
Group type: OTHER
Intervention: Papanicolaou test
Study: NCT00081263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT01002703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bendamustine, Prednisone
Description: During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
Study: NCT01819558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recwt1-A10+AS01B
Study: NCT03651518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kineret
Description: 100 mg, once/day sc 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira
Description: 40 mg/15 days sc 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stelara
Description: 45 mg/12 weeks sc, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosentyx
Description: 300mg sc every week for 1 month, then 300 mg/month sc for 5 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roactemra
Description: 480 mg/perf/4 weeks 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 2 sessions of 1000 mg at inclusion and 15 days after inclusion
Study: NCT02003066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard fluid therapy
Description: In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative fluid therapy
Description: In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
Study: NCT03741946

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Triangle of Sedillot identification using ultrasonography
Description: Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
Study: NCT03866538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of Oral Budesonide
Description: The intervention arm will taper and stop budesonide therapy (withdrawal).
Study: NCT02110472

Intervention type: DEVICE
Group type: OTHER
Intervention: Corneal inlay
Description: Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
Study: NCT01531933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS3233
Description: For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
Study: NCT01157949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: Study patients will receive 1.5 mg/kg/day intravenously for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thymoglobulin
Description: Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
Study: NCT02012998

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBVAXPRO 5µg
Description: 0.5mL intramuscular injection
Study: NCT03114813

Intervention type: DRUG
Intervention: Carvedilol
Description: Non-selective beta-blocker as per routine clinical care

Intervention type: OTHER
Intervention: MRI scan
Description: One hour non-invasive MRI scan

Intervention type: PROCEDURE
Intervention: Hepatic Venous Pressure Gradient (HVPG)
Description: Second HVPG to evaluate treatment response
Study: NCT05601258

Intervention type: OTHER
Intervention: Age, gender, hospitalization and mortality rates will be compared
Description: Age, gender, hospitalization and mortality rates will be compared

Intervention type: OTHER
Intervention: Age, gender, hospitalization and mortality rates will be compared
Description: Age, gender, hospitalization and mortality rates will be compared
Study: NCT02107027

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nMARQ catheter
Description: In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navistar catheter
Description: In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted.
Study: NCT02315781

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
Study: NCT03269942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular Flow-Diversion
Description: Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral Revascularization
Description: Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
Study: NCT01531933

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DLBS3233
Description: For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of \< 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
Study: NCT03755362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Dental evaluation at baseline, 3, 6, and 9 months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive Treatment
Description: Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to \<20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
Study: NCT00877890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2.0mg, once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide twice daily
Description: subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
Study: NCT00652522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD/CRT implant
Description: Implantation of a ICD/ CRT device if not yet implanted

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD/CRT implant
Description: Implantation of a ICD/ CRT device if not yet implanted

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: Atrial Fibrillation ablation by pulmonary vein isolation
Study: NCT02377193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG Fresenius
Description: Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
Study: NCT01669356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenteral supplement with enteral nutrition for patients after esophagectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral Nutrition alone for patients after esophagectomy
Study: NCT00042770

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: talc
Description: Given intrapleurally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dyspnea management
Description: No talc
Study: NCT03566927

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FLEX Scoring Catheter with Lutonix DCB
Description: Treatment by the FLEX Scoring Catheter, a plain balloon angioplasty, followed by a Lutonix DCB.